No abstract

Based on the authors' experience, Artecoll is a safe, viable option for long-term treatment of deep facial wrinkles, nasal asymmetry, hypoplastic or atrophic lips, and depressed acne scars, and the results have been accompanied by a high degree of patient satisfaction. Although the implant is often palpable, rarely does it cause significant visible lumps. Its use and applications as a semipermanent injectable agent certainly warrant further investigation.

Intralobar pulmonary sequestration is a rare congenital malformation characterized by the presence of dysplastic lung that does not communicate with the tracheobronchial tree, and has aberrant systemic arterial supply. While most are asymptomatic, they rarely can present with hemoptysis, which has been traditionally managed with surgical resection of the sequestration. We report a case of an 18-year-old male who presented with acute large-volume hemoptysis on a background of recurrent minor episodes of hemoptysis, due to intralobar sequestration. He was successfully treated with transarterial embolization with a combination of polyvinyl alcohol (PVA) particles, gelfoam and coils. Transarterial embolization can be effective in managing emergent hemoptysis from pulmonary sequestration.

No abstract

No abstract

Highly selected patients with lung cancer invading the spine can potentially be cured with induction chemoradiation therapy followed by radical en bloc resection of the tumor. A multidisciplinary operative strategy allows a significant chance of achieving complete resection in patients requiring multilevel hemivertebrectomy or total vertebrectomy and an appreciable cure rate.

No abstract

Purpose: To evaluate initial response and overall survival (OS) of neuroendocrine tumor (NET) liver metastases initially treated with transarterial embolization (TAE) using spherical particles of different sizes. Methods: A single-institution retrospective review was performed of 160 patients with NET liver metastases initially treated with TAE using < 100 μm (n=77) or only ≥ 100 μm (n=83) spherical particles. For each patient, we evaluated: initial response by mRECIST, time to progression, overall survival, complications, primary site, tumor grade and degree of differentiation, volume of liver disease, extrahepatic disease, NET-related symptoms, comorbidities, Child Pugh score, performance status, lobar versus selective embolization, and arteriovenous shunting. Results: Initial response was higher for TAE using particles <100 μm versus TAE using only particles ≥100 μm (64% vs 42%, p=0.007). Multivariate logistic regression showed that use of * Corresponding author. Conflict of interest: FEB is a co-founder of Claripacs, LLC. He received research funding (investigator-initiated) and support for research meetings from Guerbet. He received research support (investigator-initiated) from GE. He received research supplies (investigator-initiated) from Bayer. He received a research grant and speaker fees from Society of Interventional Oncology, which were sponsored by Guerbet. He is an investor in Labdoor, Qventus, CloudMedx, and Notable Labs. Compliance with ethical standards Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required. This HIPAA-compliant retrospective study was approved by the IRB. Informed consent: For this type of study informed consent is not required. This study has obtained IRB approval from Memorial Sloan Kettering Cancer Center and the need for informed consent was waived. Consent for publication: For this type of study consent for publication is not required.